Edition:
India

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

14.47USD
16 Feb 2018
Change (% chg)

$-0.96 (-6.22%)
Prev Close
$15.43
Open
$15.38
Day's High
$15.38
Day's Low
$13.89
Volume
891,751
Avg. Vol
650,352
52-wk High
$18.24
52-wk Low
$7.70

Chart for

About

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical,... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $1,364.26
Shares Outstanding(Mil.): 112.47
Dividend: --
Yield (%): --

Financials

BRIEF-Mimedx Comments On Magistrate Recommendation In Co's Lawsuit Against Short Sellers

* MIMEDX COMMENTS ON MAGISTRATE RECOMMENDATION IN THE COMPANY'S LAWSUIT AGAINST SHORT SELLERS

18 Jan 2018

BRIEF-Mimedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of Amniofix

* MIMEDX ANNOUNCES FIRST PATIENTS HAVE BEEN ENROLLED IN THE PHASE 3 CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN PATIENTS WITH RECALCITRANT PLANTAR FASCIITIS PAIN

16 Jan 2018

BRIEF-Mimedx Settles Patent Infringement Lawsuit

* MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE

12 Jan 2018

BRIEF-MiMedx Agrees To Lawsuit Settlement With Former Employee

* MIMEDX GROUP INC - COMPANY HAS AGREED TO A CONFIDENTIAL LAWSUIT SETTLEMENT FROM ONE FORMER EMPLOYEE

19 Dec 2017

BRIEF-MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln

* MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION

13 Dec 2017

BRIEF-MiMedx Says It Expects To Exceed Top End Of Q4 Revenue Guidance Of $88 Mln

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED TOP END OF FOURTH QUARTER REVENUE GUIDANCE OF $88 MILLION

30 Nov 2017

BRIEF-Mimedx provides update on its reimbursement coverage

* Mimedx Group Inc - ‍provided a reimbursement update in light of FDA final and draft guidance documents related to human tissue​

21 Nov 2017

BRIEF-MiMedx Group sees FY 2017 revenue $320.6 million to $321.6 million

* MiMedx Group Inc - ‍reiterates Q4 and full year 2017 guidance​

17 Nov 2017

BRIEF-MiMedx announces Q3 2017 results

* MiMedx announces record results for third quarter of 2017 and raises full year revenue guidance

27 Oct 2017

BRIEF-Mimedx Group Inc preliminary Q3 revenue $84.6 million

* Announces third quarter revenues of $84.6 million exceeds guidance by more than 5 percent

10 Oct 2017

Competitors

  Price Chg
Shire PLC (SHP.L) 3,114.50 -87.50
Shire PLC (3159084.L) -- --
Smith & Nephew plc (SN.L) 1,265.50 -14.00

Earnings vs. Estimates